Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients
Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients
复制标题
DOI：
10.1016/j.pnpbp.2020.109945
复制
发表时间：
2020-07-13
影响因子：
5.6
通讯作者：
Martins-de-Souza, Daniel
中科院分区：
文献类型：
--
作者：
de Almeida, Valeria;Alexandrino, Guilherme L.;Martins-de-Souza, Daniel
非典型抗精神病药物被广泛用于管理精神分裂症症状。然而，这些药物可能会引起有害的副作用，如MetS，这与患者心血管风险增加有关。脂质在这方面发挥着核心作用，脂质代谢的变化与精神分裂症的病理生物学有关。此外，最近的证据表明，脂质体的变化可能与抗精神病药物治疗反应。本研究的目的是评估精神分裂症患者接受利培酮、奥氮平或奎替鲁治疗6周前后血浆样本中脂质组的变化。液相色谱串联质谱（LC-MS/MS）分析显示，所有处理组的神经酰胺（Cer）、甘油磷脂酸（PA）、甘油磷酸胆碱（PC）、磷脂酰乙醇胺（PE）、磷脂酰肌醇（PI）、甘油磷酸甘油（PG）和磷脂酰丝氨酸（PS）水平均发生变化。然而，利培酮治疗也影响二酰甘油（DG）、神经酰胺1-磷酸（CerP）、甘油三酯（TG）、鞘磷脂（SM）和神经酰胺磷酸肌醇（PI-Cer）。此外，观察到特定的脂质谱，可用于区分不同抗精神病药物的不良反应者和良好反应者。因此，在这一领域的进一步工作可能会导致基于脂质的生物标志物，可用于改善精神分裂症患者的临床管理。
Atypical antipsychotics are widely used to manage schizophrenia symptoms. However, these drugs can induce deleterious side effects, such as MetS, which are associated with an increased cardiovascular risk to patients. Lipids play a central role in this context, and changes in lipid metabolism have been implicated in schizophrenia's pathobiology. Furthermore, recent evidence suggests that lipidome changes may be related to antipsychotic treatment response. The aim of this study was to evaluate the lipidome changes in blood plasma samples of schizophrenia patients before and after 6 weeks of treatment with either risperidone, olanzapine, or quetiapine. Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis showed changes in the levels of ceramides (Cer), glycerophosphatidic acids (PA), glycerophosphocholines (PC), phosphatidylethanolamines (PE), phosphatidylinositols (PI), glycerophosphoglycerols (PG), and phosphatidylserines (PS) for all treatments. However, the treatment with risperidone also affected diacylglycerides (DG), ceramide 1-phosphates (CerP), triglycerides (TG), sphingomyelins (SM), and ceramide phosphoinositols (PI-Cer). Moreover, specific lipid profiles were observed that could be used to distinguish poor and good responders to the different antipsychotics. As such, further work in this area may lead to lipid-based biomarkers that could be used to improve the clinical management of schizophrenia patients.